Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01641809 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
A Phase 2 study of HIV Infections and Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
- 20
- Study locations
NCT01641809 is a Phase 2 study of HIV Infections and Infection, Human Immunodeficiency Virus that has completed, run by ViiV Healthcare. The registered enrollment target is 244 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT01641809, a Phase 2 study of HIV Infections and Infection, Human Immunodeficiency Virus, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to select a dose of GSK1265744 primarily on the basis of antiviral activity and tolerability in HIV-1 infected, antiretroviral naive subjects. This study consists of two parts: Induction Phase: Approximately 200 subjects will be randomized (50 subjects in each of the 4 treatment arms). The Induction Phase consists of a 24 week dose-ranging evaluation of GSK1265744 at blinded doses of 10 mg, 30 mg and 60 mg once-daily and a control arm of open-label efavirenz (EFV) 600 mg once daily. The background dual nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral therapy (ART) for all arms will be either abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) as selected by the Investigator. Subjects randomized to a GSK1265744 containing arm, who successfully complete 24 weeks on study and demonstrate virologic suppression (defined as having a plasma HIV-1 ribonucleic acid \[RNA\] \<50 copies per milliliter \[c/mL\] before Week 24, with no signs of virologic rebound) will become eligible for the Maintenance Phase of this study. Maintenance Phase: The background NRTIs will be discontinued and the subjects will continue their randomized dose of GSK1265744 in combination with rilpivirine (RPV) 25 mg once-daily for an additional 72 weeks. The Maintenance phase will evaluate the ability of this two drug ART regimen to maintain virologic suppression through Week 48, Week 72 and Week 96. Subjects randomized to the EFV arm will continue on their randomized regimen through Week 96. After completion of the maintenance phase, subjects could enroll in the Open-Label Phase to continue GSK1265744 + RPV treatment as long as they continue to derive clinical benefit and until it is locally approved and commercially available.
Conditions Studied
Interventions
- DRUG GSK1265744 10 mg
- DRUG GSK1265744 30 mg
- DRUG GSK1265744 60 mg
- DRUG Efavirenz 600 mg
- DRUG Rilpivirine 25 mg
Study Locations (20)
Florida
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Ft. Pierce
- GSK Investigational Site - Miami
- GSK Investigational Site - Oakland Park
- GSK Investigational Site - Orlando
- GSK Investigational Site - West Palm Beach
California
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Beverly Hills
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - San Francisco
District of Columbia
- GSK Investigational Site - Washington D.C.
- GSK Investigational Site - Washington D.C.
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Augusta
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Phoenix
Arkansas
- GSK Investigational Site - Little Rock
Colorado
- GSK Investigational Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2012-08-06 |
| Est. Completion | 2019-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01641809
The ClinicalTrials.gov registry entry for NCT01641809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (45% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which GSK1265744 10 mg is the first listed.
NCT01641809 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01641809 about?
NCT01641809 is a clinical study titled "Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine". The study is designed to select a dose of GSK1265744 primarily on the basis of antiviral activity and tolerability in HIV-1 infected, antiretroviral naive subjects. This study consists of two parts: Induction Phase: Approximately 200 subjects will be randomized (50 subjects in each of the 4 treatm...
What is the current status of trial NCT01641809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2012-08-06. Estimated completion is 2019-01-15.
What conditions does trial NCT01641809 study?
This clinical trial studies the following conditions: HIV Infections, Infection, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT01641809?
The interventions under investigation include: GSK1265744 10 mg (DRUG), GSK1265744 30 mg (DRUG), GSK1265744 60 mg (DRUG), Efavirenz 600 mg (DRUG), Rilpivirine 25 mg (DRUG).
Who is sponsoring clinical trial NCT01641809?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01641809 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.